{"entity":{"id":"nct04919811","kind":"trial","name":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC","aka":[],"tldr":"A phase 2 trial of Taletrectinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvation Bio Inc., active and no longer recruiting.","summary":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC is a phase 2 interventional study registered as NCT04919811 by Nuvation Bio Inc., with 217 participants enrolled, started 2021-09-01 and due to reach its primary completion in 2025-06-11. Interventions recorded: Taletrectinib. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04919811","url":"https://clinicaltrials.gov/study/NCT04919811"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["taletrectinib"],"companies":["nuvation-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04919811","phase":"2","setting":"A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients With Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors","sponsor":"Nuvation Bio Inc.","enrolled":217,"outcomes":[]},"route":"/trials/nct04919811/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"taletrectinib","kind":"drug","name":"Taletrectinib","route":"/drugs/taletrectinib/"}],"company":[{"id":"nuvation-bio","kind":"company","name":"Nuvation Bio","route":"/companies/nuvation-bio/"}]}}